Pro State of the art 2018

Focus and goals

The landscape of prostate cancer significantly changed in the last decade, due to the availability of new drugs which impressively improved the prognosis of metastatic patients. Thus, in the daily practice clinicians are challenging with patients clearly different compared to the populations enrolled in pivotal trials. To optimize the efficacy of the available drugs used in the best sequence and to choose a patient-tailored therapy is not simple in absence of head-to-head studies.

In the meeting the most critical aspects of the therapeutic algorithm were discussed: Italian clinicians had the possibility to meet some of the most important European experts in this field. The meeting was highly interactive, with short podium presentations and structured Q&A time slots, favoring the attendant involvement in the discussion.

Speaker presentations are available in .pdf format in the programme section

With the support of

Under the patronage of